Connect your AI

Envela ELA Professional Service Fees Payable

Discontinued — last reported Q4 '20

Professional Service Fees Payable at other companies

Esperion TherapeuticsESPR

$3.02M-29.5%

Oruka Therapeutics, Inc.ORKA

$775K+59.1%

AZZAZZ

$1.2M—

IDT CorporationIDT

$6.86M+93.8%

Rumble, Inc.RUM

$7.59M—

Neuropace, Inc.NPCE

$203K-73.9%

Segments

By segment

Corporate$89.05K+5.2%

Other financials

Income statement

Revenue$98.4M+104%

Gross profit$20.6M+72.3%

Operating income$11.2M+259%

Net income$8.8M+255%

EPS (diluted)$0.34+240%

Balance sheet

Cash & equivalents$38.6M+83.6%

Total debt$20.0M+11.5%

Total equity$75.9M+37.6%

Total assets$108.0M+35.5%

Cash flow

Operating cash flow$21.2M+1,771%

CapEx$567.9K+47.7%

Free cash flow$20.6M+2,658%

Valuation

Market cap$681.28M+343%

Enterprise value$662.71M+340%

P/E32.5×+11.6×

P/S2.3×+1.5×

Profitability

Gross margin21.5%-2.9pp

Operating margin9%+4.3pp

Net margin7.2%+3.3pp

FCF margin4%—

Returns & leverage

Return on equity32%+17.9pp

Debt / equity0.3×-0.1×

Current ratio3.5×-1.0×

Where this comes from

Reported directly by Envela in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Envela’s 10-K/A, filed March 26, 2021, on SEC EDGAR. View the filing →